ReviewFrontiers in oncology2026
State of high-grade glioma care in Africa: insights from a scoping review of the available published literature.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High-grade gliomas (HGGs), WHO grade 3-4 diffuse gliomas, are aggressive primary brain tumors. Evidence on their management and outcomes in Africa remains limited, unevenly distributed, and lacking population-based incidence data. This review mapped published literature on HGG epidemiology, clinical presentation, diagnosis, treatment, and outcomes across represented African countries. Methods: This review followed the Arksey and O'Malley framework, refined by Levac et al. and the Joanna Briggs Institute, and reported per PRISMA-ScR guidelines, with the protocol prospectively registered on OSF (osf.io/hkf6g). Six databases were searched (inception-January 2026) for studies of African patients with confirmed WHO grade 3-4 gliomas; quality was appraised by two reviewers using JBI tools. Data were synthesized descriptively and stratified by study design, with no meta-analytic pooling. Results: Twenty-five studies (2008-2025) reporting 1,212 patients from 11 of 54 African countries were included; 312 (25.7%) were excluded as non-HGG or unconfirmed, leaving 900 in the confirmed cohort. Most studies were retrospective (56%), concentrated in Morocco (36%), Nigeria, and Côte d'Ivoire (16% each); 20% were case reports or small series. Raised intracranial pressure, motor deficits, and seizures showed mean study-level frequencies of 62%, 61%, and 41% (in 14, 12, and 11 of 25 studies). MRI was reported in 80% of studies; advanced imaging was rarely available. Glioblastoma predominated (833/900, 92.6%), and molecular testing (IDH, MGMT) was inconsistent. Gross total resection was achieved in a minority of patients; no study reported intraoperative adjuncts (neuronavigation, fluorescence guidance). Mortality at last follow-up ranged from 16.1%-100% (upper value from a single four-patient case series). Median overall survival ranged from 11-14 months, closely approximating median follow-up (11.7 months); these figures should be interpreted as descriptive rather than statistically estimated survival. Conclusion: Within evidence from 11 of 54 African countries, HGG care shows major diagnostic and therapeutic disparities and regional inequalities; findings should not be generalized continent-wide. Investment in infrastructure, training, molecular diagnostics, funding, and regional collaboration is needed to improve outcomes, equity of care, and evidence representativeness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.